Skip to main content
. Author manuscript; available in PMC: 2020 Oct 7.
Published in final edited form as: Schizophr Res. 2019 Dec 2;216:443–449. doi: 10.1016/j.schres.2019.10.051

Table 2.

Demographics and clinical data of participants.

Mean ± SD N
Age at CHR-P Onset 17.60 ± 3.63 92
Female, No. (%) 35 (38.04) 92
APS, No. (%) 88 (95.65) 92
BIPS, No. (%) 9 (9.78) 92
GRD, No. (%) 15 (16.30) 92
SPD diagnosis, No. (%) 10 (10.87) 92
SOPS Positive Score 13.62 ± 3.65 91
SOPS Negative Score 12.44 ± 6.37 91
SOPS Disorganization Score 6.38 ± 3.77 91
SOPS General Score 9.75 ± 4.27 91
Calculated Baseline Risk of Conversion 26.20% ± 12.65 92
Decline in GAF in the Past Year 13.98 ± 12.56 92
Decline in GFR in the Past Year 1.54 ± 1.79 92
Decline in GFS in the Past Year 0.99 ± 1.15 92

SOPS = Scale Of Psychosis-risk Symptoms; GFR Change = change in Global Role Function score in the year prior to baseline assessment; GFS Change = change in Global Social Function score in the year prior to baseline; GAF Change = change in Global Assessment of Functioning score in the year prior to baseline assessment; Baseline BIPS = presence of Brief Intermittent Psychosis Syndrome at baseline assessment; Baseline APS = presence of Attenuated Psychotic Symptom Syndrome at baseline assessment; Baseline GRD = presence of Genetic Risk and Deterioration Syndrome at baseline assessment; Baseline SPD = presence of Schizotypal Personality Disorder at baseline assessment; Calculated Risk = subject-wise calculated risk using the NAPLS Risk Calculator; Average Tanner Stage = self-reported average of pubic and penile/breast development at baseline assessment.

HHS Vulnerability Disclosure